American taxpayers may get shortchanged by a deal between the feds and Mylan Pharmaceuticals over Medicaid rebates, according to a new analysis.
How so? Let’s follow the math: After crunching some numbers, researchers found that Mylan should have paid Medicaid at least $538 million in rebates for its EpiPen device during a recent three-year period, which is more than four times what the company actually paid to the health care program.
About the Author Reprints
